The objective of the study was to evaluate the prognostic value of P-selectin and sCD40L levels related to the evolution of recurrent thrombosis in patients withantiphospholipid syndrome (APS).
Material and methods. Forty one patients with APS, mean age 47.87 ± 12.91 years, 30 women, were followed-up for 24 months for the evolution with recurrent thrombosis. Serum P-selectin and sCD40L levels were assessed using a standardised ELISA method (R&D Minneapolis, USA) at baseline and 12 months thereafter. Twenty healthy subjects, with similar demographic characteristics, served as controls. Statistics: t test / ANOVA / Mann-Whitney U tests, Pearson /
Spearman correlation tests, multivariate followed by logistic regression (SPSS 22.0.0). The study was approved by the local Ethics Committee and each enrolled patient signed an informed consent.
Results. Patients with APS showed significantly higher P-selectin levels than control group (219.04±146.24 vs. 94.20±20.75 ng/dL, P<0.0003). Logistic regression analysis revealed serum P selectin as an independent predictor of recurrent thrombosis in patients with APS (OR=1.01, 95% CI 1.0004-1.0207, P=0.0028).
Conclusion. P-selectin proved to be an independent predictor of recurrent thrombosis in patients with APS.
Key words: antiphospholipid syndrome, P-selectin, sCD40L, recurrent thrombosis.
sCD40L: soluble CD40L
APS: antiphospholipid syndrome
LA: lupus anticoagulant
aPL: antiphospholipid antibodies
aCL: anticardiolipin antibodies
PAPS: primary antiphospholipid syndrome
SLE: systemic lupus erythematous
INR: international normalized ratio